Boston Scientific BSX underwent analysis by 18 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 8 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 8 | 5 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $98.06, a high estimate of $110.00, and a low estimate of $86.00. Surpassing the previous average price target of $90.44, the current average has increased by 8.43%.
Decoding Analyst Ratings: A Detailed Look
The standing of Boston Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $100.00 | $98.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $101.00 | $98.00 |
| Lee Hambright | Bernstein | Raises | Outperform | $100.00 | $92.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $100.00 | $92.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $98.00 | $95.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $98.00 | $87.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $98.00 | $92.00 |
| William Plovanic | Canaccord Genuity | Maintains | Buy | $98.00 | $98.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $110.00 | $100.00 |
| Bob Hopkins | B of A Securities | Raises | Buy | $100.00 | $90.00 |
| Joshua Jennings | TD Cowen | Raises | Buy | $100.00 | $86.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $98.00 | $88.00 |
| Rick Wise | Stifel | Raises | Buy | $100.00 | $85.00 |
| Mike Matson | Needham | Maintains | Hold | $86.00 | $86.00 |
| Marie Thibault | BTIG | Raises | Buy | $93.00 | $84.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $100.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $95.00 | $85.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $90.00 | $82.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Boston Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Get to Know Boston Scientific Better
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Boston Scientific's Financial Performance
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 19.34% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boston Scientific's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.25%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Boston Scientific adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
